|

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

RECRUITINGSponsored by Tanta University
Actively Recruiting
SponsorTanta University
Started2025-07-10
Est. completion2025-11-01
Eligibility
Age28 Weeks – 36 Weeks
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07154134

Summary

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Eligibility

Age: 28 Weeks – 36 WeeksHealthy volunteers accepted
Inclusion Criteria:

* Prematurity.
* Gestational age between 28 and 36 weeks.
* Suffering from respiratory distress syndrome.

Exclusion Criteria:

* Intrauterine growth restriction (IUGR).
* Hypoxic ischemic encephalopathy.
* Multiple congenital anomalies.
* Chromosomal abnormalities.
* Preterm less than 28 weeks.
* Neonates with a maternal history of chorioamnionitis (early sepsis).
* Infant of diabetic mother.
* Prelabor rupture of membranes (PROM)\> 2 hours.

Conditions6

CopeptinDiabetesEndocanPreterm NeonatesRespiratory Distress SyndromeSerum

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.